Scientific publications

Download the publications

2025 ECCO 2025: Lusvertikimab is efficacious in severe ulcerative colitis (UC) patients with high fecal calprotectin (FCP): results from the CoTikiS study
2025 ECCO 2025: Anti-IL-7 receptor plus anti-IL12/23 combination induces complete histological normalization in chronic colitis
2025 ECCO 2025: Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe ulcerative colitis: results of a multicenter, randomized, placebo-controlled phase II study (CoTikiS)
2024 OSE279, a PD-1 blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: preliminary results of a First-In-Human (FIH) study in subjects with advanced malignancies, 2024 ESMO Targeted Anticancer Therapies
2023 Antagonist antibodies inhibiting the binding of myeloid checkpoint CLEC-1 to novel endogenous ligands demonstrate high anti-tumor efficacies in humanized preclinical models, SITC 2023
2023 Anti-PD-1/IL-7v immunocytokine (BICKI®IL7v) favors proliferation & survival of TCF1+ stem like memory T cells and a durable in vivo efficacy in monotherapy or using combinatorial strategies, CICON 2023
2023 Open-label, Phase I dose escalation/expansion trial of the anti-SIRPa monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab, ESMO 2023
2023 OSE279, a PD-1 blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preclinical characterization and early clinical results of a First-In-Human (FIH) study in subjects with advanced malignancies, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
2023 ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression, Frontiers in Immunology, Juillet 2023
2023 Agonist anti-ChemR23 mAb inhibits NETosis and neutrophil-mediated inflammation, FOCIS 2023
2023 Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation, 2023 American Association for Cancer Research (AACR)
2023 TRIM21 is a novel endogenous partner of the inhibitory myeloid checkpoint CLEC-1 involved in tumor antigen cross-presentation, 2023 American Association for Cancer Research (AACR)
2023 CD127 is expressed by acute lymphoblastic leukemias and is efficiently targeted by Lusvertikimab (OSE-127) through IL-7Rα blockade and antibody dependent phagocytosis, 2023 American Association for Cancer Research (AACR)
2023 Anti-PD-1/IL-7v bispecific antibody (BICKI®IL7v) promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy, 2023 American Association for Cancer Research (AACR)
2023 Predictive response biomarkers from a Phase I clinical trial of a SIRPalpha inhibitor, BI 765063, stand-alone and in combination with ezabenlimab, a PD-1 inhibitor, in patients with advanced solid tumors, 2023 American Association for Cancer Research (AACR)
2023 First-in-Human Study in Healthy Subjects with the Non-Cytotoxic 1 Monoclonal Antibody OSE-127, a Strict Antagonist of the IL-7Rα, Journal of Immunology, Feb. 2023
2022 “CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy”, Science Advances, Nov. 2022
2022 “IL7R TME expression correlates with immunotherapy response and is associated with T-cell stemness with decreased apoptosis”, SITC 2022
1 2 3 4 5

To receive OSE Immunotherapeutics’ latest news